Int J Oral Maxillofac Surg:SSRO或MDO骨骼推进术可改善中重度OSA患者的生活质量

2020-10-01 MedSci原创 MedSci原创

骨骼推进手术与矢状裂纹肌截骨术(SSRO)或下颌骨远端成骨术(MDO)在治疗阻塞性睡眠呼吸暂停(OSA)患者中效果显著,并可改善其生活质量(QoL)。本研究旨在评估中重度OSA患者在骨骼推进手术后的纵

骨骼推进手术与矢状裂纹肌截骨术(SSRO)或下颌骨远端成骨术(MDO)在治疗阻塞性睡眠呼吸暂停(OSA)患者中效果显著,并可改善其生活质量(QoL)。本研究旨在评估中重度OSA患者在骨骼推进手术后的纵向QoL变化,研究结果已在线发表于Int J Oral Maxillofac Surg。

研究共纳入18名患者,随机接受SSRO(n=9)或MDO(n=9)单独或作为骨骼推进手术的一部分。与对照组(n=36)的基线QoL进行比较。在术后2年对比SSRO组和MDO组的QoL。采用Epworth睡意量表(ESS)、卡尔加里睡眠呼吸暂停生活质量指数(SAQLI)、睡眠功能结果问卷(FOSQ)和短表健康调查(SF-36)作为工具。OSA组术前的ESS、SF-36、FOSQ、SAQLI均比对照组差。MDO和SSRO组在术后各时间点的ESS均有显著改善(P≤0.021)。术后2年两组的FOSQ、SAQLI、SF-36与对照组相似。SSRO组和MDO组之间的QoL没有差异。

 

综上所述,本研究结果表明,中重度OSA患者经SSRO或MDO骨骼推进手术后,QoL得到改善。

 

原始出处:

 

W K TsuiY Yang, et al., Improvement in quality of life after skeletal advancement surgery in patients with moderate-to-severe obstructive sleep apnoea: a longitudinal study. Int J Oral Maxillofac Surg. 2020 Mar;49(3):333-341. doi: 10.1016/j.ijom.2019.07.007. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1956809, encodeId=51d01956809d0, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Thu Aug 26 10:11:39 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020656, encodeId=37912020656f3, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Mon Mar 29 12:11:39 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349791, encodeId=d9461349e9128, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Oct 03 13:11:39 CST 2020, time=2020-10-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1956809, encodeId=51d01956809d0, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Thu Aug 26 10:11:39 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020656, encodeId=37912020656f3, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Mon Mar 29 12:11:39 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349791, encodeId=d9461349e9128, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Oct 03 13:11:39 CST 2020, time=2020-10-03, status=1, ipAttribution=)]
    2021-03-29 小几洁
  3. [GetPortalCommentsPageByObjectIdResponse(id=1956809, encodeId=51d01956809d0, content=<a href='/topic/show?id=7647e210ac' target=_blank style='color:#2F92EE;'>#FAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7210, encryptionId=7647e210ac, topicName=FAC)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/B389FA68ECBF51BE2FE14093CF61F6AE/100, createdBy=eb8e2500096, createdName=夏天与十三菇凉, createdTime=Thu Aug 26 10:11:39 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020656, encodeId=37912020656f3, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Mon Mar 29 12:11:39 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349791, encodeId=d9461349e9128, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Oct 03 13:11:39 CST 2020, time=2020-10-03, status=1, ipAttribution=)]
    2020-10-03 bioon3

相关资讯

Acta Otolaryngol:Z型腭咽成形术联合70度内窥镜部分切除术治疗严重阻塞性睡眠呼吸暂停症

患有严重阻塞性睡眠呼吸暂停(OSA)的患者需要安全有效的手术治疗。本研究旨在评估通过70度内窥镜辅助消融(Eco-TBR)对严重OSA进行Z-pal咽成形术(ZPPP)和部分舌切除术的疗效。

Asian Pac J Allergy Immunol:鼻内皮质激素治疗中度到重度阻塞性睡眠呼吸暂停且并发慢性鼻炎患者的效果研究

慢性鼻炎与阻塞性睡眠呼吸暂停(OSA)是常见的并存疾病。目前关于鼻内类固醇疗效的证据很少。最近,有研究人员评估了鼻内类固醇对中重度OSA且并存慢性鼻炎的疗效。

Am J Resp Crit Care:减肥对阻塞性睡眠呼吸暂停严重程度的影响

接受ILI减肥的OSA和2型糖尿病参与者在治疗10年时降低了OSA严重程度。ILI和DSE组在10年时OSA严重程度无差异。

Eur Respir J:轻度至中度阿尔茨海默氏病患者阻塞性睡眠呼吸暂停和认知功能下降

该研究可观察到OSA组的ADAS-cog评分比非OSA组更好,虽有统计学意义,但无临床意义。随访1年后,研究人员在不同的认知亚领域或总体认知方面均未发现差异。

Eur Respir J:阻塞性睡眠呼吸暂停治疗与血压的关系

尽管该荟萃分析显示,CPAP/MAD预期的降血压效应为中等,但它确定了可以预测CPAP在血压控制方面可明显受益的患者特征。这些发现应谨慎解释,但是在确定OSA治疗患者与BP降低相关的潜在特征时,它们尤其重要。

Diabetes Care:阻塞性睡眠呼吸暂停合并心血管疾病患者持续气道正压治疗、血糖与糖尿病风险

在已确诊的心血管疾病和阻塞性睡眠呼吸暂停患者中,该研究并未发现CPAP治疗对糖尿病或糖尿病前期或糖尿病风险患者的血糖控制有影响。